Events

Upcoming Events

June 7, 2014
The Bay Area Biotechnology Symposium: Pharmaceuticals for the Future, San Francisco
Henry Lowman, Ph.D., chief scientific officer, scheduled to give a presentation titled “Targeting Antibodies Specifically to Diseased Tissues with the Probody™ Platform”

Past Events

April 5-9, 2014
AACR Annual Meeting 2014, San Diego

Two posters will be presented by CytomX scientists on Monday, April 7, 2014 from 1:00-5:00 p.m. (PT). Details as follows:

Presentation Title: An anti-Jagged- 1/-2 Probody demonstrates inhibition of Jagged-dependent Notch signaling and is activated in multiple types of tumors
Location: Hall A-E, Poster Section 31
Poster Board Number: 25

Presentation Title: Transforming Notch ligands into tumor-antigen targets: A Probody-Drug Conjugate (PDC) targeting Jagged 1 and Jagged 2
Location: Hall A-E, Poster Section 31
Poster Board Number: 26

March 31-April 2, 2014
Human Antibodies & Hybridomas 2014, Vienna, Austria
Henry Lowman, Ph.D., chief scientific officer, delivered a presentation on April 1 titled “Targeting antibodies specifically to diseased tissues with Probodies”

March 25-26, 2014
Boston Biotech Business Development Conference, Boston

January 13-17, 2014
Cambridge Healthtech Institute's 12th Annual PEP Talk: The Protein Sciences Week Pipeline 3: Biotherapeutics, Palm Springs, California

January 11-12, 2014
BBC East West CEO Conference, San Francisco

December 12, 2013
Probodies Expand the Therapeutic Index of Antibodies and ADCs, Huntington Beach, California

December 10-14, 2013
San Antonio Breast Cancer Symposium, San Antonio

December 7-10, 2013
2013 ASH Annual Meeting, New Orleans

November 5, 2013
BIOEurope 2013, Vienna, Austria

October 19-23, 2013
AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, Boston

October 14-17, 2013
World ADC Summit, San Francisco

October 8-9, 2013
12th Annual BIO Investor Forum, San Francisco

September 19, 2013
Cancer Advance Conference, Boston
Sean McCarthy, D. Phil., chief executive officer, participated in panel titled, "Cancer in 15 Years: Predictions"

June 24-26, 2013
The 30th International Conference On Advances in the Applications of Monoclonal in Clinical Oncology and Symposium on Cancer Stem Cells, Mykonos, Greece
James West, Ph.D., research fellow at CytomX, delivered a presentation titled “The Probody™ Platform Enables Tumor Targeted Therapies.” Jason Sagert, senior scientist, delivered a presentation titled “An Anti-Jagged Probody Enables Tumor-specific Inhibition of Jagged-Dependent Notch Signaling.”

June 26-28, 2013
The Third International Conference on Notch Targeting in Cancer, Mykonos, Greece
James West, Ph.D., research fellow at CytomX, delivered a presentation titled "Probodies: protease activated antibodies for disease-specific inhibition of Notch Signaling". Jason Sagert, senior scientist, delivered a presentation titled "An Anti-Jagged Probody Enables Tumor-specific Inhibition of Jagged-Dependent Notch Signaling."

June 12, 2013
Empowered Antibodies Congress 2013, Barcelona
Sean McCarthy, D. Phil., chief executive officer, delivered a presentation titled "Probody™ therapeutics expand the universe of potential ADC targets."

May 3, 2013
Ninth Annual PEGS, Boston
Henry Lowman, Ph.D., chief scientific officer, delivered a presentation titled "Probody™ Therapeutics Enable an Expanded Universe of ADC Targets."

April 9, 2013
AACR Annual Meeting, Washington, D.C.
Luc Desnoyers, Ph.D., director of cell biology, delivered an oral presentation titled "Development of a Proteolytically Activatable EGFR Probody™ for Cancer Therapy" during the "Back to the Future" mini-symposium.

January 28, 2013
Keystone Symposium on Antibodies as Drugs, Vancouver
Henry Lowman, Ph.D., chief scientific officer, presented a short talk titled, "Probody™ Therapeutics: A New Class of Proteolytically Activated Antibodies."

January 7, 2013
Biotech Showcase, San Francisco
Sean McCarthy, D. Phil, chief executive officer, delivered an overview of the company.

January 6, 2013
East / West CEO Conference, San Francisco
Sean McCarthy, D. Phil, chief executive officer, participated as a speaker at the "West Coast and International Perspectives" session.

November 14, 2012
BIO-Europe, Hamburg, Germany
Sean McCarthy, D. Phil, chief executive officer, presented an overview of the company.

November 9, 2012
Human Antibodies and Hybridomas, Orlando, Florida
Henry Lowman, Ph.D., chief scientific officer, delivered a presentation titled "Preclinical efficacy and safety of Probody™ therapeutics."

June 25, 2012
Next Generation Protein Therapeutics Summit, San Diego
Henry Lowman, Ph.D., chief scientific officer, presented on “Safety and Efficacy of Probody™ Therapeutics in Preclinical Models”

June 18, 2012
2012 BIO International Convention, Boston

May 30, 2012
Euro-Biotech Partnering Summit, Paris

April 29, 2012
PEGS Biologics Partnering Forum, Boston

February 19, 2012
Molecular Med Tri-Con 2012, San Francisco
Henry Lowman, Ph.D., chief scientific officer, delivered a presentation titled “Proteolytically Activated Antibodies have the Potential to Expand Therapeutic Index and Open Up New Target Space.”

January 9, 2012
BioTech Showcase, San Francisco
Sean McCarthy, D. Phil, chief executive officer, presented an overview of the company.

December 6, 2011
IBC Antibody Engineering / Therapeutics Conference, San Diego
Henry Lowman, Ph.D., chief scientific officer, presented.

November 7 - 9, 2011
Human Antibodies and Hybridomas Conference, Cannes, France
Henry Lowman, Ph.D., chief scientific officer, presented.

November 1, 2011
BioEurope – 2011, Dusseldorf, Germany

October 24 - 26, 2011
BioNetwork West, Laguna Niguel, California

June 22, 2011
Next Generation Protein Therapeutics Summit, San Francisco
Henry Lowman, Ph.D., vice president of research, presented.